Biotech Values

[DewDiligence]

IDIX 2009-2010 Clinical Goals

[Updated for disclosures on 10/5/09 JMP webcast.]


HCV

AASLD meeting (10/30-11/3/09): IDIX to present the full dataset from the IDX184 monotherapy study.

4Q09: NVS decision on whether to license IDX184. If NVS opts in, an IDX184 partnership deal will be inked by year-end; if not, IDIX will then be free to pursue a partnership deal with another company.

4Q09: Begin European phase-1 trial of IDX375. (A CTA was submitted during 3Q09.)

4Q09: Submit IND or CTA for IDX316. Start phase-1 trial in 1Q010.

4Q09/1Q10: Start phase-2 trial of SoC ± IDX184. (See further details in paragraph 3 of #msg-42212057.)

Mid 2010: Report top-line results of phase-2 trial of SoC ± IDX184.

2H10(?): Submit IND or CTA for lead compound from NS5A program.


HIV

Early 2010: GSK (as the operator of the GSK-PFE joint venture) to start phase-2 trial of IDX899 vs Sustiva.